IL34 and colorectal carcinoma: Accumulating evidence supports the view that IL-34-driven activation of MCSF-1R in different cell types present in the CRC mass triggers signalling pathways that sustain either directly or indirectly CRC cell growth, survival and diffusion as well as resistance to anti-tumor therapeutics.